A prospective, randomized, double-blind placebo-controlled multi-centre dose-finding study of 3 different regimens of gpASIT+TM administered subcutaneously to adult patients with grass pollen-induced allergic rhinoconjunctivitis

Trial Profile

A prospective, randomized, double-blind placebo-controlled multi-centre dose-finding study of 3 different regimens of gpASIT+TM administered subcutaneously to adult patients with grass pollen-induced allergic rhinoconjunctivitis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2015

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BTT-gpASIT008
  • Sponsors BioTech Tools
  • Most Recent Events

    • 11 Jun 2015 According to an ASIT Biotech media release, results from this trial were presented at the International Congress organized by teh European Academiy of Allergy and Clinical Immunology 2015.
    • 24 Apr 2015 Status changed from recruiting to completed as per European Clinical Trials Database.
    • 15 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top